Examkin

Soru

Zorluk: OrtaPreventive Care and Screening

A 43-year-old female patient presents to the ambulatory clinic for a routine wellness examination. She has a past medical history of severe seropositive rheumatoid arthritis, which has been well-controlled for the past two years on a regimen of methotrexate and adalimumab. She has no other chronic medical conditions. She is a former smoker with a 10 pack-year history, having quit five years ago. Her screening mammogram at age 42 was normal, and a Pap smear with high-risk human papillomavirus (HPV) testing performed one year ago was negative. Her immunization records indicate she received a tetanus, diphtheria, and acellular pertussis (Tdap) booster three years ago, an intramuscular inactivated influenza vaccine two weeks ago, and a 20-valent pneumococcal conjugate vaccine (PCV20) one year ago. Her vital signs are normal, and physical examination shows no active joint inflammation. Which of the following is the most appropriate next step in preventive care for this patient?

  1. Administer the recombinant zoster vaccineCevap
  2. B
    Administer the live-attenuated varicella vaccine
  3. C
    Administer the 23-valent pneumococcal polysaccharide vaccine
  4. D
    Schedule a screening colonoscopy
  5. E
    Order a low-dose chest computed tomography scan

Cevap

The most appropriate next step is to administer the recombinant zoster vaccine because the patient is over 19 years old and is pharmacologically immunosuppressed due to her rheumatoid arthritis medications.
The correct recommendation is to administer the recombinant zoster vaccine. According to the Advisory Committee on Immunization Practices (ACIP), the two-dose recombinant zoster vaccine (RZV) series is recommended for all adults aged 19 years and older who are immunodeficient or immunosuppressed due to disease or therapy. This patient's regimen of methotrexate and adalimumab (a tumor necrosis factor inhibitor) significantly increases her risk for herpes zoster and its complications, making RZV indicated now despite her being under the standard age of 50.

Adım Adım Çözüm

1
Analyze the patient's demographics, past medical history, and current medications.
The patient is a 43-year-old female with rheumatoid arthritis on methotrexate and adalimumab (a TNF inhibitor).
Identifying immunosuppressive therapy is critical, as it alters both the indications for and contraindications to specific vaccines.
2
Evaluate the patient's current immunization and cancer screening status against age and risk-factor specific guidelines.
She is up to date on pneumococcal vaccination (PCV20 complete), influenza, Tdap, cervical cancer screening, and breast cancer screening. She is not yet old enough for routine colorectal or lung cancer screening.
Determining missing routine and risk-specific preventive care is the core task of a wellness examination.
3
Apply specialized Advisory Committee on Immunization Practices (ACIP) guidelines for immunocompromised adults.
Adults aged 19 years and older who are immunosuppressed due to disease or therapy should receive the two-dose recombinant zoster vaccine (RZV) series.
While standard zoster vaccination begins at age 50, immunocompromise is a specific indication that lowers the starting age.
4
Verify safety and absolute contraindications for the planned intervention.
RZV is a non-live vaccine and is safe for this patient. Conversely, any live-attenuated vaccines (e.g., varicella, MMR) are strictly contraindicated due to her biologic therapy.
Administering a live vaccine to an immunosuppressed patient carries a high risk of disseminated disease.

Anahtar Kavram

Immunization guidelines for immunocompromised adults (Recombinant Zoster Vaccine indication and live vaccine contraindications).
Bu soruyu puanla

Konular

Preventive Care and Screening

Bu konudan daha fazla soru